2. Academic Validation
  3. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy

Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy

  • Curr Opin Investig Drugs. 2008 Jan;9(1):101-7.
John R Pollard 1
Affiliations

Affiliation

  • 1 Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. john.pollard@uphs.upenn.edu
PMID: 18183537
Abstract

UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z